Zydus Lifesciences Completes Assertio Holdings Merger

Zydus Lifesciences Limited has announced the successful completion of its merger with Assertio Holdings Inc. through its wholly owned subsidiary, Zara Merger Sub Inc. Following the merger, Assertio has become a wholly owned subsidiary of Zydus Lifesciences, and its common stocks are no longer listed on the Nasdaq Global Market. The acquisition involved an offer price of USD 23.50 per share in cash, with a total consideration of USD 166.33 million. Assertio is a US-based specialty oncology pharmaceutical company with a key product, ROLVEDON®, approved by the USFDA. This strategic move aims to acquire outstanding shares and gain full control over Assertio.